-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $194

Benzinga·08/01/2025 10:37:28
Listen to the news
HC Wainwright & Co. analyst Andrew Fein maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $187 to $194.